Although tumor-infiltrating lymphocytes (TILs) are key mediators of anti-tumor immunity, their prognostic value in CRC remains context-dependent, and the role of CD274 (PD-L1) protein in modulating TIL activity in this setting remains controversial [28–32]. Here, CD274 is linked to neoplasm.